PDCD1 and melanoma: A phase I/II trial (NCT02608268) evaluated MGB453 (anti-TIM3) in combination with PDR001 (anti-PD-1) in advanced solid cancers such as melanoma and NSCLC and showed excellent safety profile and preliminary antitumor activity (170).